Plans Progress for Approval of Omaveloxolone

Plans Progress for Approval of Omaveloxolone

307858

Plans Progress for Approval of Omaveloxolone

Reata Pharmaceuticals is planning to ask the U.S. Food and Drug Administration (FDA) to approve omaveloxolone to treat people with Friedreich’s ataxia (FA) early in 2022, following the completion of a preliminary meeting with the agency. “Omaveloxolone could be the first drug approved for the treatment of Friedreich’s ataxia — actually the first drug approved for any ataxia,” Susan Perlman, MD, professor of neurology at the University of California, Los Angeles, said in a press release.…

You must be logged in to read/download the full post.